Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:38:29.164Z.
Consensus retrieved: 2026-10-06T14:00:11.472Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:38:29.164Z.
Quote observation: 2026-10-06T14:35:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 619c5482a9d59cec4bb20d2c4447c35828cdfaa1e6076b938dd954a9c5cde0ad
Forward PE Ratio (N/A) = Dated Quote Price ($22.54) / Consensus Forward EPS ($-4.49)
FORWARD PE RATIO
N/A
Mineralys Therapeutics, Inc.
Market Cap
$1.99B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $1.99B | N/A |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $1.99B | 16.42 |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.00B | 57.91 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.01B | N/A |
| AxoGen, Inc. (AXGN)vs › | $1.97B | 82.72 |
| Immunome, Inc. (IMNM)vs › | $1.95B | N/A |
| Alvotech (ALVO)vs › | $2.05B | N/A |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.93B | N/A |
| Azenta, Inc. (AZTA)vs › | $1.93B | 84.26 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.08B | 26.01 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $22.54, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.49 | $-4.60 – $-4.44 | 6 | n/m |
| 2027-12-31 | $-2.43 | $-3.50 – $-1.52 | 6 | n/m |
| 2028-12-31 | $-1.21 | $-1.91 – $-0.43 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
